Animesh Petkar, MD
Ophthalmology · Fresno, CANPI 1417121054
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,335 of the $44,172 with a category attached, or 98.1%. Baxter Healthcare accounts for 98.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $26,480 and has fallen 99.4% since, to $148 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $803.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$43K
- Amgen$283
- Welch Allyn$150
- Astellas Pharma US Inc$76
- Mallinckrodt Hospital Products Inc.$49
- Dompe US, Inc.$48
- plus $231 from 8 others
What the payments were for
- Consulting fees$43,33598%
- Speaking & faculty fees$1500%
- Food & beverage$6872%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 21 | $43,335 |
| Amgen(2 entities) | 14 | $283 |
| Welch Allyn | 1 | $150 |
| Astellas Pharma US Inc | 3 | $76 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Dompe US, Inc. | 2 | $48 |
| Novartis | 2 | $45 |
| Sun Pharmaceutical Industries Inc. | 3 | $42 |
| Alcon | 1 | $38 |
| Genentech USA, Inc. | 2 | $35 |
| Alimera Sciences, Inc. | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $16 |
| Oyster Point Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,172 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 269 | $1,551 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 60 | $879 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 84 | $843 |
| Prednisolone Acetate | 17 | $724 |
| Timolol Maleate | 33 | $446 |
| Brimonidine Tartrate | 39 | $317 |
| Dorzolamide Hcl | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Fresno
- William MaxwellFresno$448K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.